Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

NCT05954143 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Metastatic Breast Cancer
HER2-positive Breast Cancer

Interventions

DRUG: BDC-1001
DRUG: Pertuzumab

Sponsor

Bolt Biotherapeutics, Inc.

Collaborators

[object Object]